• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜后肉瘤:重复切除的结果。

Retroperitoneal sarcomas: Outcomes of repeated resections.

作者信息

Hwang Hyeonuk, Kwon Yoon-Hye, Lim Han-Ki, Kim Jeesun, Park Kyu Joo

机构信息

Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.

出版信息

Korean J Clin Oncol. 2020 Dec;16(2):96-103. doi: 10.14216/kjco.20015. Epub 2020 Dec 31.

DOI:10.14216/kjco.20015
PMID:36945717
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9942735/
Abstract

PURPOSE

Retroperitoneal sarcomas (RPS) are rare malignant tumors arising from mesenchymal cells. The objective of this study was to review the treatment experiences and to identify prognostic factors for overall survival (OS) after primary resection and subsequent reoperations for recurrences.

METHODS

The medical records of patients who underwent resection for RPS at our institution between June 2002 and December 2016 were retrospectively reviewed. Univariate and multivariable Cox proportional hazards modeling was used to assess the prognostic factors for OS.

RESULTS

A total of 48 patients were enrolled. On multivariable analysis in primary resection group, the FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) grade was a significant prognostic factor for OS (P=0.006). The patients who received chemotherapy after primary resection were significantly associated with poor prognosis (P=0.009). The 5-year OS rate after primary resection (n=48) were 58.1% and the 5-year cumulative reoperation rate after primary resection was 62.5%. After second resection for recurrence after primary resection (n=23), the 5-year OS rate was 64.3%. There was a tendency towards decreased surgery-free survival rate as the number of repeated resections for recurrent RPS increased. In the subset of patients (n=16) who underwent more than 3 repeated resections at our institute, the 5-year OS rate was 75.0%, indicating that repeated resections are not associated with worse outcome.

CONCLUSION

Only low tumor grade was an independent favorable prognostic factor for OS. Although the prognosis for RPS remains poor, repeated resections for recurrence are not associated with poor prognosis. Aggressive surgical strategies for recurred RPS patients are warranted.

摘要

目的

腹膜后肉瘤(RPS)是起源于间充质细胞的罕见恶性肿瘤。本研究的目的是回顾治疗经验,并确定初次切除及后续复发再手术患者总生存期(OS)的预后因素。

方法

回顾性分析2002年6月至2016年12月在我院接受RPS切除术患者的病历。采用单因素和多因素Cox比例风险模型评估OS的预后因素。

结果

共纳入48例患者。在初次切除组的多因素分析中,法国国立癌症中心联合会(FNCLCC)分级是OS的显著预后因素(P=0.006)。初次切除后接受化疗的患者预后明显较差(P=0.009)。初次切除后的5年OS率(n=48)为58.1%,初次切除后的5年累计再手术率为62.5%。初次切除后复发进行二次切除(n=23),5年OS率为64.3%。随着复发性RPS重复切除次数的增加,无手术生存期有下降趋势。在我院接受3次以上重复切除的患者亚组(n=16)中,5年OS率为75.0%,表明重复切除与较差的预后无关。

结论

仅肿瘤低分级是OS的独立有利预后因素。尽管RPS的预后仍然很差,但复发后的重复切除与预后不良无关。对于复发性RPS患者,积极的手术策略是必要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/28a140abc5d9/kjco-16-2-96f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/8499cb0d3ecd/kjco-16-2-96f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/0d414f66e73c/kjco-16-2-96f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/2b46ea1472e8/kjco-16-2-96f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/69302afbaa4f/kjco-16-2-96f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/cf5a13f10339/kjco-16-2-96f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/6f10056a9f3e/kjco-16-2-96f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/28a140abc5d9/kjco-16-2-96f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/8499cb0d3ecd/kjco-16-2-96f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/0d414f66e73c/kjco-16-2-96f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/2b46ea1472e8/kjco-16-2-96f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/69302afbaa4f/kjco-16-2-96f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/cf5a13f10339/kjco-16-2-96f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/6f10056a9f3e/kjco-16-2-96f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ebe/9942735/28a140abc5d9/kjco-16-2-96f7.jpg

相似文献

1
Retroperitoneal sarcomas: Outcomes of repeated resections.腹膜后肉瘤:重复切除的结果。
Korean J Clin Oncol. 2020 Dec;16(2):96-103. doi: 10.14216/kjco.20015. Epub 2020 Dec 31.
2
Recurrent retroperitoneal sarcomas: Clinical outcomes of surgical treatment and prognostic factors.复发性腹膜后肉瘤:手术治疗的临床结果和预后因素。
Eur J Surg Oncol. 2021 May;47(5):1201-1206. doi: 10.1016/j.ejso.2020.08.030. Epub 2020 Sep 9.
3
A better overall survival (OS) for total (ipsilateral) retroperitoneal lipectomy than standard complete resection in patients with retroperitoneal liposarcoma: a comparative multi-institutional study.对于腹膜后脂肪肉瘤患者,全(同侧)腹膜后脂肪切除术的总生存期(OS)优于标准根治性切除术:一项多机构比较研究。
Ann Transl Med. 2022 Jul;10(14):785. doi: 10.21037/atm-22-3332.
4
Outcome after surgical resection of multiple recurrent retroperitoneal soft tissue sarcoma.多次复发腹膜后软组织肉瘤切除术后的结果。
Eur J Surg Oncol. 2021 Aug;47(8):2189-2200. doi: 10.1016/j.ejso.2021.04.040. Epub 2021 May 4.
5
Fédération Nationale Des Centres de Lutte Contre Le Cancer (FNCLCC) Grading, Margin Status and Tumor Location Associate With Survival Outcomes in Malignant Peripheral Nerve Sheath Tumors.法国抗癌联盟(FNCLCC)分级、切缘状态和肿瘤位置与恶性外周神经鞘瘤的生存结果相关。
Am J Clin Oncol. 2022 Jan 1;45(1):28-35. doi: 10.1097/COC.0000000000000877.
6
Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group.腹膜后肉瘤初次扩大切除术后复发后的结局:跨大西洋腹膜后肉瘤工作组的报告
Cancer. 2017 Jun 1;123(11):1971-1978. doi: 10.1002/cncr.30572. Epub 2017 Feb 2.
7
Tumor grade and symptoms at presentation are survival risk factors in Chinese patients with primary retroperitoneal sarcoma.肿瘤分级和初诊时的症状是中国原发性腹膜后肉瘤患者的生存风险因素。
J Clin Transl Res. 2022 Nov 24;8(6):584-593. eCollection 2022 Dec 29.
8
Characteristics and Outcomes of Locally Recurrent Retroperitoneal Sarcoma After First Relapse in a Single Tertiary Asian Centre and Applicability of the .亚洲某单一三级中心首次复发后局部复发性腹膜后肉瘤的特征及预后,以及(此处原文不完整,无法准确翻译最后部分)的适用性
Front Oncol. 2021 Nov 25;11:730292. doi: 10.3389/fonc.2021.730292. eCollection 2021.
9
Retroperitoneal Sarcoma Requiring Abdominal Aortic Replacement With Long-Term Survival: A Case Report.需要进行腹主动脉置换并长期存活的腹膜后肉瘤:一例报告
Cureus. 2024 May 13;16(5):e60198. doi: 10.7759/cureus.60198. eCollection 2024 May.
10
Novel Nomograms-Based Prediction Models for Patients with Primary Undifferentiated Pleomorphic Sarcomas Resections.基于新型列线图的原发性未分化多形性肉瘤切除患者预测模型
Cancers (Basel). 2021 Apr 15;13(8):1917. doi: 10.3390/cancers13081917.

引用本文的文献

1
Radical resection and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of high risk recurrent retroperitoneal sarcoma-A pilot study in a tertiary Asian centre.根治性切除术联合腹腔内热灌注化疗(HIPEC)治疗高危复发性腹膜后肉瘤——亚洲一家三级医院的初步研究
PLoS One. 2024 Apr 4;19(4):e0300594. doi: 10.1371/journal.pone.0300594. eCollection 2024.

本文引用的文献

1
Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review.高分化脂肪肉瘤和去分化脂肪肉瘤:最新综述。
Semin Diagn Pathol. 2019 Mar;36(2):112-121. doi: 10.1053/j.semdp.2019.02.006. Epub 2019 Feb 28.
2
Current principles of surgery for retroperitoneal sarcomas.腹膜后肉瘤的当前手术原则。
J Surg Oncol. 2018 Jan;117(1):33-41. doi: 10.1002/jso.24919. Epub 2018 Jan 8.
3
Surgical morbidity in retroperitoneal sarcoma resection.腹膜后肉瘤切除术的手术并发症
J Surg Oncol. 2018 Jan;117(1):56-61. doi: 10.1002/jso.24902. Epub 2018 Jan 3.
4
Multiply recurrent retroperitoneal liposarcoma.多次复发的腹膜后脂肪肉瘤
J Surg Oncol. 2018 Jan;117(1):62-68. doi: 10.1002/jso.24929. Epub 2017 Dec 19.
5
Systemic therapy in retroperitoneal sarcoma management.腹膜后肉瘤治疗中的全身治疗
J Surg Oncol. 2018 Jan;117(1):87-92. doi: 10.1002/jso.24933. Epub 2017 Nov 30.
6
Radiation therapy in retroperitoneal sarcoma management.腹膜后肉瘤治疗中的放射治疗。
J Surg Oncol. 2018 Jan;117(1):93-98. doi: 10.1002/jso.24892. Epub 2017 Nov 22.
7
Treatment of retroperitoneal sarcoma: current standards and new developments.腹膜后肉瘤的治疗:当前标准与新进展
Curr Opin Oncol. 2017 Jul;29(4):260-267. doi: 10.1097/CCO.0000000000000377.
8
Retroperitoneal liposarcoma: the role of adjuvant radiation therapy and the prognostic factors.腹膜后脂肪肉瘤:辅助放疗的作用及预后因素
Radiat Oncol J. 2016 Sep;34(3):216-222. doi: 10.3857/roj.2016.01858. Epub 2016 Sep 28.
9
Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma.在治疗单灶性原发性腹膜后脂肪肉瘤时,术前放射治疗联合根治性手术切除与较低的局部复发率相关。
J Surg Oncol. 2016 Dec;114(7):814-820. doi: 10.1002/jso.24427. Epub 2016 Sep 16.
10
Retroperitoneal Sarcoma: Fact, Opinion, and Controversy.腹膜后肉瘤:事实、观点与争议
Surg Oncol Clin N Am. 2016 Oct;25(4):697-711. doi: 10.1016/j.soc.2016.05.003. Epub 2016 Jul 30.